Years Active: 2025
Title: Ingo Focken: Innovator in Immunotherapy
Introduction
Ingo Focken is a notable inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on binding proteins that target specific receptors involved in immune responses.
Latest Patents
Focken holds a patent for "Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering." This patent describes multifunctional binding proteins that consist of two antigen binding domains (ABDs) and a portion of an immunoglobulin Fc region. The first ABD specifically binds to human BCMA, while the second ABD binds to human NKp46. Additionally, the immunoglobulin Fc region is designed to bind to a human Fc-γ receptor. This invention has potential applications in the treatment or prevention of proliferative disorders, including multiple myeloma.
Career Highlights
Throughout his career, Ingo Focken has focused on advancing therapeutic strategies that leverage the immune system to combat diseases. His work has been instrumental in developing novel approaches to enhance the efficacy of immune cell therapies.
Collaborations
Focken has collaborated with notable colleagues, including Nicolas Gourdin and Laurent Gauthier, to further his research and development efforts in the field of immunotherapy.
Conclusion
Ingo Focken's innovative contributions to immunotherapy, particularly through his patent on NK cell engagers, highlight his role as a key figure in advancing medical science. His work continues to pave the way for new treatment options for patients with proliferative disorders.